SDZ 224-015

SDZ 224-015 is an orally active inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1. SDZ 224-015 possesses anti-COVID-19 activity, targeting Mpro (IC50 of 30 nM) [1][2].

Product Specifications

CAS Number

[161511-45-1]

UNSPSC

12352005

Target

Caspase; Interleukin Related; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/sdz-224-015.html

Purity

96.05

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(OCC1=CC=CC=C1)N[C@@H](C(C)C)C(N[C@@H](C)C(N[C@@H](CC(OCC)=O)C(COC(C2=C(C=CC=C2Cl)Cl)=O)=O)=O)=O

Molecular Formula

C30H35Cl2N3O9

Molecular Weight

652.52

References & Citations

[1]Martin A Redhead, et al. Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19. Sci Rep. 2021 Jun 24;11 (1) :13208.|[2]P R Elford, et al. Reduction of inflammation and pyrexia in the rat by oral administration of SDZ 224-015, an inhibitor of the interleukin-1 beta converting enzyme. Br J Pharmacol. 1995 Jun;115 (4) :601-6.